Elanco Animal Health (NYSE:ELAN) Issues FY 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 0.800-0.860 for the period, compared to the consensus EPS estimate of 0.900. The company issued revenue guidance of $4.4 billion-$4.5 billion, compared to the consensus revenue estimate of $4.5 billion. Elanco Animal Health also updated its FY25 guidance to $0.80-$0.86 EPS.

Analyst Ratings Changes

A number of research firms have recently commented on ELAN. Stifel Nicolaus reduced their price objective on shares of Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating on the stock in a research note on Friday, February 21st. Morgan Stanley cut their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Wednesday. Leerink Partners started coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They set a "market perform" rating and a $14.00 target price on the stock. UBS Group cut their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday. Finally, Barclays cut their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Elanco Animal Health has a consensus rating of "Hold" and a consensus target price of $15.83.

Elanco Animal Health Stock Up 2.4 %

NYSE ELAN traded up $0.27 on Friday, hitting $11.19. 6,902,175 shares of the company were exchanged, compared to its average volume of 4,960,017. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The stock has a fifty day moving average of $11.71 and a 200-day moving average of $13.03. Elanco Animal Health has a 12 month low of $10.20 and a 12 month high of $18.80. The company has a market cap of $5.53 billion, a PE ratio of 27.96, a PEG ratio of 2.50 and a beta of 1.42.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the company posted $0.08 EPS. The business's quarterly revenue was down 1.4% on a year-over-year basis. As a group, analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.